Für Ärzte/Ärztinnen
Ich lege großen Wert auf eine vertrauensvolle Zusammenarbeit mit dem zuweisenden Arzt. Gern stelle ich mich Ihnen auch persönlich vor. Sie erreichen mich unter 0176 52020 181 oder senden Sie mir eine Nachricht, dann rufe ich zurück!
Ergänzende Links zu Studien und anderen Dokumenten:
REIZDARM
Changes in Fecal Calprotectin After Rifaximin Treatment in Patients With Nonconstipated Irritable Bowel Syndrome (IBS).
https://www.ncbi.nlm.nih.gov/pubmed/30611316
A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study.
https://www.ncbi.nlm.nih.gov/pubmed/30406392
Launch of ibs-smart™, an advancement in blood testing for Irritable Bowel Syndrome (IBS)
Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.
https://www.ncbi.nlm.nih.gov/pubmed/28451914
Cedars-Sinai Research Identifies Gut Gas Linked to Diarrhea (Hydrogen Sulfide)
https://www.cedars-sinai.org/newsroom/cedars-sinai-research-identifies-gut-gas-linked-to-diarrhea/
Review of rifaximin as treatment for SIBO and IBS
https://www.ncbi.nlm.nih.gov/pubmed/19243285
Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth.
https://www.ncbi.nlm.nih.gov/pubmed/29508268
Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949258/
Update on Irritable Bowel Syndrome Diagnostics and Therapeutics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969781/
IBSchek - The First Clinically Validated Blood Test for IBS with Predominant Diarrhea (IBS-D) and Mixed Symptoms (IBS-M)
http://www.commdx.com/irritable-bowel-syndrome.html
Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome
https://www.ncbi.nlm.nih.gov/pubmed/11151884/
25 % aller Nicht-Antibiotika schädigen Darmbakterien
https://www.ernaehrungsmedizin.blog/2018/03/20/hunderte-medikamente-schaedigen-darmbakterien/
Proton pump inhibitors (PPI) therapy and risk of C. diff. infection: Systematic review and meta-analysis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643276/
FODMAP
Kluyveromyces marxianus-Hefe ermöglicht die Herstellung von FODMAP-armem Vollkornbrot
https://www.ncbi.nlm.nih.gov/pubmed/30166134
Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs
https://www.ncbi.nlm.nih.gov/pubmed/28740352
Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467063/
Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918736/
A diet low in FODMAPs reduces symptoms of irritable bowel syndrome
https://www.ncbi.nlm.nih.gov/pubmed/24076059
Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome
SIBO
A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study.
https://www.ncbi.nlm.nih.gov/pubmed/30406392
Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth.
https://www.ncbi.nlm.nih.gov/pubmed/29508268
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
https://www.ncbi.nlm.nih.gov/pubmed/21208106
Treatment of SIBO
http://www.townsendletter.com/FebMarch2015/sibo0215_2.html
Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949258/
How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach
https://www.ncbi.nlm.nih.gov/pubmed/26780631
Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome
https://www.ncbi.nlm.nih.gov/pubmed/11151884/
Review of rifaximin as treatment for SIBO and IBS
https://www.ncbi.nlm.nih.gov/pubmed/19243285
Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504364/
Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.
https://www.ncbi.nlm.nih.gov/pubmed/20852272
A 14-day elemental diet is highly effective in normalizing the lactulose breath test
https://www.ncbi.nlm.nih.gov/pubmed/14992438
Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome
https://www.ncbi.nlm.nih.gov/pubmed/22523730
Two Independent Networks of Interstitial Cells of Cajal Work Cooperatively with the Enteric Nervous System to Create Colonic Motor Patterns
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153851/
Update on Irritable Bowel Syndrome Diagnostics and Therapeutics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969781/
Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.
https://www.ncbi.nlm.nih.gov/pubmed/20937045
Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system (also known as Saccharomyces cerevisiae HANSEN CBS 5926)
METHANOGENE
Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath
https://www.ncbi.nlm.nih.gov/pubmed/22573345
Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway
HYDROGENSULFID (Flat-Line Test Results / "Non-Responder")
Hydrogen Sulfide Dysbiosis: A Case Study ("Flat Line" Breath Test Result)
https://ndnr.com/gastrointestinal/hydrogen-sulfide-dysbiosis-a-case-study/
Hydrogen sulphide in exhaled breath: a potential biomarker for small intestinal bacterial overgrowth in IBS.
https://www.ncbi.nlm.nih.gov/pubmed/27163246
Cedars-Sinai Research Identifies Gut Gas Linked to Diarrhea (Hydrogen Sulfide)
https://www.cedars-sinai.org/newsroom/cedars-sinai-research-identifies-gut-gas-linked-to-diarrhea/
SIFO (Small Intestinal Fungal Overgrowth)
BIOFILM
Biofilm formation of mucosa-associated methanoarchaeal strains
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086402/
Biofilms: What Have We Learned from the Research?
http://ndnr.com/gastrointestinal/biofilms-what-have-we-learned-from-the-research/
Candida Biofilms: Threats, Challenges, and Promising Strategies
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816785/
Candida glabrata Biofilms: How Far Have We Come?
CANDIDA
Candida Biofilms: Threats, Challenges, and Promising Strategies
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816785/
Plants’ Natural Products as Alternative Promising Anti-Candida Drugs
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628516/
Candida glabrata Biofilms: How Far Have We Come?
MCAS (Mastcell Activation Syndrome)
What is Mast Cell Activation Syndrome (MCAS)?
https://www.drtaniadempsey.com/mastcellactivationsyndrome
Ein Webinar von Dr. Afrin (in Englisch) zum Thema MCAS gibt es am Seitenende der folgenden Website:
https://www.drtaniadempsey.com/aboutdrafrin
Characterization of Mast Cell Activation Syndrome
https://www.ncbi.nlm.nih.gov/pubmed/28262205
Meilenstein in der Diagnostik von Mastzellerkrankungen
https://www.ukb.uni-bonn.de/42256BC8002AF3E7/vwWebPagesByID/27D4C009920E64E6C12571FD003AF0D8
Fragebogen Mastzell-Erkrankungen - Patientenversion
Full List of Publications and Presentations by Lawrence B. Afrin, M.D.
http://mastcellresearch.com/full-list-of-publications-and-presentations-by-lawrence-b-afrin-md/
Dr. Theoharis C. Theoharides
https://www.mastcellmaster.com/
The Mastocytosis Society